TRUH
VanEck Healthcare TruSector ETF
TRUH
VanEck Healthcare TruSector ETF
-
NAV$28.06
as of July 10, 2026 -
Performance since inception9.30%
as of July 10, 2026 -
Total Net Assets$841.85K
as of July 10, 2026 -
Total Expense Ratio0.10%
-
Inception Date04/01/2026
Overview
Why TRUH
- Full Market Cap Sector ExposureProvides comprehensive market capitalization exposure to healthcare stocks unlike many traditional sector ETFs
- Reduced Benchmark DeviationAvoids persistent underweighting of largest sector constituents that may cause performance drift
- Precision Sector Allocation ToolDesigned to help asset allocators track sector benchmarks with greater accuracy
About TRUH
VanEck Healthcare TruSector ETF (the “Fund”) is an actively managed ETF that seeks long-term capital appreciation by investing in securities of healthcare-related companies or instruments that provide exposure to healthcare-related companies.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 04/01/26 |
|
|---|---|---|---|---|---|---|---|---|
| TRUH (NAV) | 6.57 | -- | -- | -- | -- | -- | -- | 7.85 |
| TRUH (Market Price) | 6.54 | -- | -- | -- | -- | -- | -- | 7.82 |
| MarketVector Top US Health Care Companies Index | 6.39 | 8.52 | -- | -- | -- | -- | -- | 7.69 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 04/01/26 |
|
|---|---|---|---|---|---|---|---|---|
| TRUH (NAV) | 6.57 | -- | -- | -- | -- | -- | -- | 7.85 |
| TRUH (Market Price) | 6.54 | -- | -- | -- | -- | -- | -- | 7.82 |
| MarketVector Top US Health Care Companies Index | 6.39 | 8.52 | -- | -- | -- | -- | -- | 7.69 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 07/09/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets |
Market Value (US$) |
|---|---|---|---|
|
LLY |
Eli Lilly & Co | 16.49 | 139,949 |
|
JNJ |
Johnson & Johnson | 10.68 | 90,685 |
|
ABBV |
Abbvie Inc | 7.57 | 64,227 |
|
UNH |
Unitedhealth Group Inc | 6.71 | 56,982 |
|
MRK |
Merck & Co Inc | 5.29 | 44,900 |
|
AMGN |
Amgen Inc | 3.34 | 28,362 |
|
TMO |
Thermo Fisher Scientific Inc | 3.34 | 28,334 |
|
GILD |
Gilead Sciences Inc | 2.88 | 24,406 |
|
ABT |
Abbott Laboratories | 2.81 | 23,883 |
|
ISRG |
Intuitive Surgical Inc | 2.52 | 21,401 |
|
PFE |
Pfizer Inc | 2.37 | 20,103 |
|
CVS |
Cvs Health Corp | 2.25 | 19,123 |
|
VRTX |
Vertex Pharmaceuticals Inc | 2.16 | 18,371 |
|
DHR |
Danaher Corp | 2.12 | 18,030 |
|
BMY |
Bristol-Myers Squibb Co | 2.03 | 17,208 |
|
SYK |
Stryker Corp | 1.93 | 16,356 |
|
MDT |
Medtronic Plc | 1.82 | 15,407 |
|
MCK |
Mckesson Corp | 1.59 | 13,478 |
|
ELV |
Elevance Health Inc | 1.58 | 13,452 |
|
CI |
Cigna Group/The | 1.31 | 11,088 |
|
REGN |
Regeneron Pharmaceuticals Inc | 1.18 | 10,019 |
|
BSX |
Boston Scientific Corp | 1.14 | 9,718 |
|
HCA |
Hca Healthcare Inc | 1.11 | 9,407 |
|
COR |
Cencora Inc | 1.00 | 8,469 |
|
CAH |
Cardinal Health Inc | 0.94 | 7,948 |
|
EW |
Edwards Lifesciences Corp | 0.90 | 7,672 |
|
HUM |
Humana Inc | 0.80 | 6,762 |
|
IDXX |
Idexx Laboratories Inc | 0.72 | 6,145 |
|
BDX |
Becton Dickinson & Co | 0.71 | 6,034 |
|
A |
Agilent Technologies Inc | 0.65 | 5,477 |
|
WAT |
Waters Corp | 0.62 | 5,280 |
|
IQV |
Iqvia Holdings Inc | 0.59 | 5,015 |
|
CNC |
Centene Corp | 0.54 | 4,597 |
|
ZTS |
Zoetis Inc | 0.54 | 4,580 |
|
RMD |
Resmed Inc | 0.52 | 4,377 |
|
GEHC |
Ge Healthcare Technologies Inc | 0.50 | 4,270 |
|
BIIB |
Biogen Inc | 0.49 | 4,177 |
|
VEEV |
Veeva Systems Inc | 0.49 | 4,173 |
|
DXCM |
Dexcom Inc | 0.48 | 4,089 |
|
MRNA |
Moderna Inc | 0.46 | 3,905 |
|
MTD |
Mettler-Toledo International Inc | 0.46 | 3,864 |
|
WST |
West Pharmaceutical Services Inc | 0.42 | 3,577 |
|
LH |
Labcorp Holdings Inc | 0.39 | 3,332 |
|
DGX |
Quest Diagnostics Inc | 0.39 | 3,329 |
|
STE |
Steris Plc | 0.36 | 3,024 |
|
INCY |
Incyte Corp | 0.34 | 2,844 |
|
VTRS |
Viatris Inc | 0.33 | 2,761 |
|
ZBH |
Zimmer Biomet Holdings Inc | 0.29 | 2,498 |
|
COO |
Cooper Cos Inc/The | 0.23 | 1,989 |
|
PKI |
Perkinelmer Inc | 0.21 | 1,807 |
|
ALGN |
Align Technology Inc | 0.21 | 1,782 |
|
BAX |
Baxter International Inc | 0.20 | 1,685 |
|
TECH |
Bio-Techne Corp | 0.19 | 1,636 |
|
CRL |
Charles River Laboratories Internationa | 0.19 | 1,635 |
|
SOLV |
Solventum Corp | 0.19 | 1,595 |
|
PODD |
Insulet Corp | 0.19 | 1,583 |
|
UHS |
Universal Health Services Inc | 0.15 | 1,242 |
|
HSIC |
Henry Schein Inc | 0.14 | 1,174 |
|
DVA |
Davita Inc | 0.14 | 1,147 |
|
2602335D |
Tpg Inc | 0.00 | 0 |
|
-USD CASH- |
-- | -0.24 | -2,053 |
|
-- |
Other/Cash | 0.06 | 470 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
Fees
Distributions
as of 07/10/2026
Quarterly
1.53%
1.21%
--
Distribution History
| Year | Ex-date |
Record Date |
Payable date |
Dividend Income‡ |
Short-Term Capital Gains |
Long-Term Capital Gains |
Return of Capital |
Total Distributions |
|---|---|---|---|---|---|---|---|---|
| 2026 | 07/01/2026 | 07/01/2026 | 07/07/2026 | $ 0.0847 | -- | -- | -- | $ 0.08 |
‡All registered investment companies are obliged to distribute portfolio gains to shareholders at yearend regardless of performance. Trading VanEck ETFs will also generate tax consequences and transaction expenses. The information provided is not intended to be tax advice. Tax consequences of dividend distributions may vary by individual taxpayer. There is no guarantee that dividends will be paid. To receive a distribution, you must have been a registered shareholder of the relevant VanEck ETFs on the record date. Distributions are paid to shareholders on the payment date. Past distributions are not indicative of future distributions.
Certain distributions may constitute a return of capital, which will have the effect of reducing your cost basis in the Fund’s shares and thereby increasing the amount of capital gain, if any, or decreasing the amount of capital loss, if any, that you will realize when selling or exchanging Fund shares. The final determination of the tax characteristics cannot be determined until after each Fund’s yearend and are reported to shareholders on Form 1099-DIV. The form is mailed to shareholders shortly after calendar yearend specifying how the distributions paid by the Fund during the prior calendar year should be characterized for purposes of reporting the distribution on a shareholder’s tax return.
The tax treatment and characterization of the Fund’s distributions may vary significantly from time to time depending on whether the Fund has gains or losses on the securities in its portfolio. The Fund’s distributions will normally reflect past and projected net investment income, and may include income from dividends and interest, capital gains and/or a return of capital. The final composition of the tax characteristics of the distributions cannot be determined with certainty until after the end of the year, and will be reported to shareholders at that time. The amount of distributions will vary, depending on a number of factors. As portfolio and market conditions change, the rate of dividends may change. There can be no assurance that the Fund will be able to declare a dividend distribution in each period. Past performance is no guarantee of future results.
Team
Resources
Key Documents
-
Name
Frequency - Annually
- Annually
- Annually
-
Statement of Additional Information (SAI)
Annually -
VanEck Yearend Dividends/Distributions
Annually -
NAV & Premium/Discount History
Daily - Daily
- Quarterly
Thought Leadership
-
Name
Frequency -
Access Mega Trends with Thematic ETFs
AdHoc